{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:42:12Z","timestamp":1786984932656,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.autrev.2020.102509","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T16:14:47Z","timestamp":1584029687000},"page":"102509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors"],"prefix":"10.1016","volume":"19","author":[{"given":"Caterina","family":"Bodio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pregnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Biggioggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Murgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bendtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Orietta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102509_bb0005","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102509_bb0010","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.autrev.2019.102421","article-title":"The giants (biologicals) against the pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102509_bb0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102509_bb0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","article-title":"The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis","volume":"16","author":"Pecoraro","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102509_bb0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: Implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102509_bb0030","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: The story so far","volume":"57","author":"Jani","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102509_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2015.00109","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102509_bb0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/FTD.0000000000000310","article-title":"Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations","volume":"38","author":"van Bezooijen","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.autrev.2020.102509_bb0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ab.2018.11.018","article-title":"Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques","volume":"566","author":"Real-Fern\u00e1ndez","year":"2019","journal-title":"Anal Biochem"},{"key":"10.1016\/j.autrev.2020.102509_bb0050","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2020.102509_bb0055","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00296-014-3032-0","article-title":"Practical application of acid dissociation in monitoring patients treated with adalimumab","volume":"34","author":"Llinares-Tello","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2020.102509_bb0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2020.102509_bb0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies\u2014toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2020.102509_bb0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/17425255.2017.1360280","article-title":"Biological anti-TNF drugs: Immunogenicity underlying treatment failure and adverse events","volume":"13","author":"Prado","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.autrev.2020.102509_bb0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: Causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102509_bb0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","article-title":"Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn\u02bcs disease","volume":"35","author":"Steenholdt","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.autrev.2020.102509_bb0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102509_bb0090","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102509_bb0095","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The disease activity score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102509_bb0100","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.21784","article-title":"A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and\/or anti\u2013tumor necrosis factor \u03b1 agents","volume":"54","author":"Lurati","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102509_bb0105","first-page":"37","article-title":"A coefficient of agreement for nominalscales","volume":"20","author":"Cohen","year":"1960","journal-title":"Psychol Bull"},{"key":"10.1016\/j.autrev.2020.102509_bb0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.autrev.2020.102509_bb0115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.autrev.2015.05.001","article-title":"New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis","volume":"14","author":"Meroni","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102509_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2015.12.015","article-title":"Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab","volume":"453","author":"Pavlov","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2020.102509_bb0125","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102509_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","article-title":"The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study","volume":"83","author":"Hoxha","year":"2016","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.autrev.2020.102509_bb0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis","volume":"48","author":"Quistrebert","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102509_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","article-title":"Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: A review from clinical trials and regulatory documents","volume":"34","author":"Strand","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2020.102509_bb0145","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2020.102509_bb0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2018.02.013","article-title":"Support of precision medicine through risk-stratification in autoimmune liver diseases -histology, scoring systems, and non-invasive markers","volume":"17","author":"Bossen","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102509_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:57Z","timestamp":1761599877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1568997220300616"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102509","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102509"}}